Global Infertility Drugs Market (2018-2022) with Bayer, Ferring, Merck and Novartis Dominating – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global
Infertility Drugs Market 2018-2022”
report has been added to ResearchAndMarkets.com’s
offering.

Global infertility drugs market to grow at a CAGR of 4.67% during the
period 2018-2022.

The report has been prepared based on an in-depth market analysis with
inputs from industry experts. The report covers the market landscape and
its growth prospects over the coming years. The report also includes a
discussion of the key vendors operating in this market.

One trend in the market is raising awareness regarding infertility in
couples. There is growing awareness about sexual health such as
fertility issues across the globe. This is expected to act as a positive
trend in the infertility treatment industry. Different government and
non-government organizations across the globe are supporting the couples
in coming forward and talking about their problem and seeking
professional help to tackle the problem.

According to the report, one driver in the market is growing lifestyle
diseases. A sedentary lifestyle is one of the major reasons causing the
chronic conditions such as diabetes, obesity, and high blood pressure in
the modern generation. Lacking physical activity and rising sedentary
lifestyle is directly expected to affect the health condition and may
further become a major cause of infertility.

Further, the report states that one challenge in the market is rising
inclination toward other modes of treatment for infertility.

Key Vendors

  • Bayer
  • Ferring
  • Merck
  • Novartis

Key Topics Covered:

Part 01: Executive Summary

Part 02: Scope of the Report

Part 03: Research Methodology

Part 04: Introduction

Part 05: Market Landscape

Part 06: Market Sizing

Part 07: Five Forces Analysis

Part 08: Pipeline Analysis

Part 09: Market Segmentation by Therapy

Part 10: Market Segmentation by Gender

Part 11: Customer Landscape

Part 12: Regional Landscape

Part 13: Decision Framework

Part 14: Drivers and Challenges

Part 15: Market Trends

Part 16: Vendor Landscape

Part 17: Vendor Analysis

For more information about this report visit https://www.researchandmarkets.com/research/nnn2c6/global?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Women’s
Health
, Sexual
and Reproductive Health Drugs